Cited by 117Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 53 of the 55 references it cites were found in a registry or an index.

Apolipoproteins as markers and managers of coronary risk

Chan, D.C.·2006·QJM

DOI 10.1093/qjmed/hcl027

Open this paper in CoChat — free account

Abstract

Coronary artery disease (CAD) is a major cause of morbidity and mortality in Western communities. Reliable indices of coronary risk assessment and targets for drug treatment are important to the management of patients. Although plasma LDL cholesterol is well established as a predictor of CAD, it may not be the best circulatory marker. Results from recent epidemiological studies and statin trials suggest that apolipoprotein B-100 (apoB), with or without apoA-I, is superior to LDL cholesterol in predicting coronary events. Measurements of apolipoproteins are internationally standardized, automated, cost-effective and more convenient and precise than those for LDL cholesterol. ApoB may also be preferable to the measurement of non-HDL cholesterol. Measurement of apolipoproteins (apoB and possibly apoA-I) should be routinely added to the routine lipid profile (cholesterol, triglycerides and high-density lipoprotein cholesterol) to assess the atherogenic potential of lipid disorders. This is particularly relevant to dyslipidaemias characterized by an elevation in plasma triglycerides. Apolipoproteins, especially apoB, could also replace the standard "lipid profile" as a target for therapy in at-risk patients.

Integrity signals

Registry

Crossref · 10.1093/qjmed/hcl027

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
The metabolic syndrome
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,317
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Bairey Merz, C. N., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.001 · Cited by 1,550
High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,227
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study
Yusuf, S., Hawken, S., & Ôunpuu, S. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.11.072 · Cited by 1,146
Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.
Ridker, P., Rifai, N., Cook, N., Bradwin, G., & Buring, J. (2005) · Journal of the American Medical Association (JAMA) · doi:10.1016/j.accreview.2005.09.030 · Cited by 832
Non–HDL Cholesterol, Apolipoproteins A-I and B 100 , Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women
Ridker, P. M., Rifai, N., Cook, N. R., Bradwin, G., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.3.326 · Cited by 744
Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime
Steinberg, D. H. (2002) · Nature Medicine · doi:10.1038/nm1102-1211 · Cited by 687
Non–High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality
Cui, Y. A., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., LANGENBERG, P. W., Bachorik, P. S., & Bush, T. L. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.11.1413 · Cited by 657
Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)
Pedersen, T. R., OLSSON, A. G., Færgeman, O., KJEKSHUS, J. K., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T. H., Þorgeirsson, G., Pyörälà, K., et al. (1998) · Circulation · doi:10.1161/01.cir.97.15.1453 · Cited by 618
Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Gotto, A. M., Whitney, E. J., Stein, E. A., Shapiro, D. R., Clearfield, M. B., Weis, S. E., Jou, J. Y., Langendörfer, A., Beere, P. A., Watson, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.5.477 · Cited by 558
High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00666-9 · Cited by 534
European guidelines on cardiovascular disease prevention in clinical practice
Backer, G. D., Ambrosioni, E., Borch‐Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2003) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.10.001 · Cited by 493
Apolipoprotein A-I and B Levels and the Risk of Ischemic Heart Disease During a Five-Year Follow-up of Men in the Que´bec Cardiovascular Study
Lamarche, B., Moorjani, S., Lupien, P. J., Cantin, B., Bernard, P.-M., Dagenais, G. R., & Despre´s, J.-P. (1996) · Circulation · doi:10.1161/01.cir.94.3.273 · Cited by 476
Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment
Sniderman, A. D., Furberg, C. D., KEECH, A. C., van Lennep, J. R., Frohlich, J., Jungner, I., & Walldius, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12663-3 · Cited by 449
Low-Density Lipoprotein Subfractions and the Long-Term Risk of Ischemic Heart Disease in Men: 13-Year Follow-Up Data From the Québec Cardiovascular Study
St-Pierre, A. C., Cantin, B., Dagenais, G. R., Mauriège, P., Bernard, P.-M., Després, J.-P., & Lamarche, B. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000154144.73236.f4 · Cited by 422
Apolipoprotein B and apolipoprotein A‐I: risk indicators of coronary heart disease and targets for lipid‐modifying therapy
Walldius, G., & Jungner, I. (2004) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01276.x · Cited by 395
Non-HDL Cholesterol as a Predictor of Cardiovascular Disease in Type 2 Diabetes
Lu, W., Resnick, H. E., Jablonski, K. A., Jones, K. L., Jain, A. K., Howard, W. J., Robbins, D. C., & Howard, B. V. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.16 · Cited by 370
International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material
Marcovina, S. M., Albers, J. J., Henderson, L. O., & Hannon, W. H. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.5.773 · Cited by 342
Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy
Grundy, S. M. (2002) · Circulation · doi:10.1161/01.cir.0000038419.53000.d6 · Cited by 309
Thrombogenic Factors and Recurrent Coronary Events
Moss, A. J., Goldstein, R. E., Marder, V. J., Sparks, C. E., Oakes, D., Greenberg, H., Weiss, H. J., Zaręba, W., Brown, M. W., Liang, C., et al. (1999) · Circulation · doi:10.1161/01.cir.99.19.2517 · Cited by 281
Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial
Simes, R. J., Marschner, I. C., Hunt, D. U., Colquhoun, D. M., SULLIVAN, D. R., Stewart, R., Hague, W. E., KEECH, A. C., Thompson, P., White, H. D., et al. (2002) · Circulation · doi:10.1161/hc1002.105136 · Cited by 250
Multivariate Assessment of Lipid Parameters as Predictors of Coronary Heart Disease Among Postmenopausal Women
Shai, I., Rimm, E. B., Hankinson, S. E., Curhan, G. C., Manson, J. E., Rifai, N., Stampfer, M. J., & Ma, J. (2004) · Circulation · doi:10.1161/01.cir.0000146339.57154.9b · Cited by 236
Non-HDL Cholesterol and Apolipoprotein B Predict Cardiovascular Disease Events Among Men With Type 2 Diabetes
Jiang, R., Schulze, M. B., Li, T., Rifai, N., Stampfer, M. J., Rimm, E. B., & Hu, F. B. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1991 · Cited by 234
Nonfasting Apolipoprotein B and Triglyceride Levels as a Useful Predictor of Coronary Heart Disease Risk in Middle-Aged UK Men
Talmud, P. J., Hawe, E., Miller, G. J., & Humphries, S. E. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000035521.22199.c7 · Cited by 230
International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B
Marcovina, S. M., Albers, J. J., Dati, F., Ledue, T. B., & Ritchie, R. F. (1991) · Clinical Chemistry · doi:10.1093/clinchem/37.10.1676 · Cited by 228
Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk
Sniderman, A. D., St-Pierre, A. C., Cantin, B., Dagenais, G. R., Després, J.-P., & Lamarche, B. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00262-5 · Cited by 224
Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels
Ballantyne, C. M., Andrews, T. C., Hsia, J. A., Kramer, J. H., & Shear, C. L. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01638-1 · Cited by 166
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
LaRosa, J. C., Grundy, S. M., & Waters, D. D. (2005) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2005.10.023 · Cited by 165
Apolipoprotein Concentrations During Treatment and Recurrent Coronary Artery Disease Events
van Lennep, J. E. R., Westerveld, H. T., van Lennep, H. W. O. R., Zwinderman, A. H., Erkelens, D. W., & van der Wall, E. E. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.11.2408 · Cited by 152
Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study
Meisinger, C., Loewel, H., Wilfried, M. R. A. Z., & Köenig, W. (2004) · European Heart Journal · doi:10.1093/eurheartj/ehi003 · Cited by 142
The Friedewald Formula Underestimates LDL Cholesterol at low Concentrations
Scharnagl, H., Nauck, M. A., Wieland, H., & März, W. (2001) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2001.068 · Cited by 139
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Auer, J., Weber, T., & Eber, B. (2004) · New England Journal of Medicine · doi:10.1056/nejm200408123510719 · Cited by 122
Lipids and CVD management: towards a global consensus
Ballantyne, C. M., Arroll, B., & Shepherd, J. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi373 · Cited by 86
A proposal to redefine familial combined hyperlipidaemia – Third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the Scientific Sessions of the European Society for Clinical Investigation
Sniderman, A. D., Cabezas, M. C., Ribalta, J., Carmena, R., de Bruin, T. W., Graaf, J. D., Erkelens, D. W., Humphries, S. E., Masana, L., Real, J. T., et al. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.00941.x · Cited by 81
How, when, and why to use apolipoprotein B in clinical practice
Sniderman, A. D. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02633-4 · Cited by 66
Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2004) · Clinical Science · doi:10.1042/cs20040108 · Cited by 50
Self-citation
Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men
Simon, A. C., Chironi, G. N., Gariépy, J., Pino, M. D., & Levenson, J. A. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.10.017 · Cited by 49
Joint role of non-HDL cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes
Schulze, M. B., Shai, I., Manson, J. E., Li, T., Rifai, N., Jiang, R., & Hu, F. B. (2004) · Diabetologia · doi:10.1007/s00125-004-1593-2 · Cited by 43
Cardiovascular disease and hyperlipidaemia
Krauss, R. M., & niemi, Y. A. K. (1994) · Current Opinion in Lipidology · doi:10.1097/00041433-199408000-00001 · Cited by 24
Comparison of the Relationships between Serum Apolipoprotein B and Serum Lipid Distributions
Kim, B. J., Hwang, S. T., Sung, K., Kim, B. S., Kang, J. H., Lee, M. H., & Park, J. R. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.052738 · Cited by 22
Apolipoproteins: the new prognostic indicator?
PACKARD, C. (2003) · European Heart Journal Supplements · doi:10.1016/s1520-765x(03)90032-0 · Cited by 19
The role of the cardiovascular specialist in the prevention of cardiovascular diseases - executive summary.
Collins-Nakai, R. L., & Dagenais, G. R. (1999) · PubMed · Cited by 18
Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial. To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
Simes, R. J., Marschner, I. C., & Hunt, D. U. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00772-9 · Cited by 15
Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)
&NA; (1998) · The Endocrinologist · doi:10.1097/00019616-199809000-00022 · Cited by 13
Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment
Sniderman, A. D., Furberg, C. D., KEECH, A. C., van Lennep, J. E. R., Frohlich, J., Jungner, I., Walldius, G., & Wägner, A. M. (2004) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(04)78954-8 · Cited by 9
Cardiovascular disease and hyperlipidaemia
Neary, R. H. (1993) · Current Opinion in Lipidology · doi:10.1097/00041433-199310000-00014 · Cited by 1

Sorted by citations

Indian Journal of Public Health Research & Development
Surwade, V. M., Ambedkar, B. S., Rohinee, & Delhi (2019) · Cited by 404
Ellagitannins, ellagic acid and vascular health
Larrosa, M., García‐Conesa, M., Espı́n, J. C., & Tomás-Barberán, F. A. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.09.005 · Cited by 390
Mechanisms of Action of trans Fatty Acids
Oteng, A., & Kersten, S. (2019) · Advances in Nutrition · doi:10.1093/advances/nmz125 · Cited by 331
Screening and Treatment for Lipid Disorders in Children and Adolescents: Systematic Evidence Review for the US Preventive Services Task Force
Haney, E. M., Huffman, L. H., Bougatsos, C., Freeman, M., Steiner, R. D., & Nelson, H. D. (2007) · PEDIATRICS · doi:10.1542/peds.2006-1801 · Cited by 202
Apolipoproteins and cancer
Ren, L., Yi, J., Li, W., Zheng, X., Liu, J., Wang, J., & Du, G. (2019) · Cancer Medicine · doi:10.1002/cam4.2587 · Cited by 145

See all 117

Authors: Chan, D. C.
Affiliations: The University of Western Australia (AU)
Corresponding author: Chan, D.C.
ORCID: Chan, D.C.
Venue: QJM
Publisher: Oxford University Press (OUP)
Published: 2006-02-27
Volume: 99
Issue: 5
Pages: 277-287
ISSN: 0033-5622 (ISSN-L)
1460-2725
1460-2393
DOI: 10.1093/qjmed/hcl027
OpenAlex: W2161147110
Cited by: 117
References: 55
Citations by year: 2026: 1 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 6 · 2021: 2 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 5 · 2016: 8 · 2015: 2 · 2014: 9 · 2013: 3 · 2012: 4
FWCI: 1.57
Type: journal article
Language: en
Open access: closed
Locations: QJM (publishedVersion)
PubMed (publishedVersion)
UWA Profiles and Research Repository (UWA) (submittedVersion)
Funders: National Heart Foundation of Australia
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: apolipoprotein B-100, apolipoprotein A-I, coronary artery disease, coronary risk assessment, LDL cholesterol, non-HDL cholesterol, dyslipidemia, triglyceride elevation, lipid profile, atherogenic lipoproteins
MeSH terms: Anticholesteremic Agents, Apolipoproteins, Apolipoproteins B, Cholesterol, Coronary Artery Disease, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Biomarkers, Apolipoprotein A-I, Risk Assessment, Apolipoprotein B-100

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Apolipoproteins as markers and managers of coronary risk

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks